Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM159PT | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.000128 | uM | 11057.155 | 0.8167 | 0.9050 | 4.1614 | |
| SUM159PT | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.00064 | uM | 11057.155 | 0.7809 | 0.8846 | 4.1614 | |
| SUM159PT | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.0032 | uM | 11057.155 | 0.7303 | 0.8545 | 4.1614 | |
| SUM159PT | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.016 | uM | 11057.155 | 0.7028 | 0.8375 | 4.1614 | |
| SUM159PT | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.08 | uM | 11057.155 | 0.5533 | 0.7348 | 4.1614 | |
| SUM159PT | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.4 | uM | 11057.155 | 0.4831 | 0.6792 | 4.1614 | |
| SUM159PT | TNBC | Basal B | Selumetinib | MEK | MAPK | 2 | uM | 11057.155 | 0.4192 | 0.6229 | 4.1614 | |
| SUM159PT | TNBC | Basal B | Selumetinib | MEK | MAPK | 10 | uM | 11057.155 | 0.4241 | 0.6275 | 4.1614 | |
| SUM159PT | TNBC | Basal B | Selumetinib | MEK | MAPK | 50 | uM | 11057.155 | 0.2846 | 0.4787 | 4.1614 | |
| SUM185PE | TNBC | Luminal | Selumetinib | MEK | MAPK | 0.000128 | uM | 12269.155 | 1.3188 | 1.8304 | 0.7969 | |
| SUM185PE | TNBC | Luminal | Selumetinib | MEK | MAPK | 0.00064 | uM | 12269.155 | 1.2665 | 1.6901 | 0.7969 | |
| SUM185PE | TNBC | Luminal | Selumetinib | MEK | MAPK | 0.0032 | uM | 12269.155 | 1.2760 | 1.7156 | 0.7969 | |
| SUM185PE | TNBC | Luminal | Selumetinib | MEK | MAPK | 0.016 | uM | 12269.155 | 1.1709 | 1.4379 | 0.7969 | |
| SUM185PE | TNBC | Luminal | Selumetinib | MEK | MAPK | 0.08 | uM | 12269.155 | 1.1531 | 1.3916 | 0.7969 | |
| SUM185PE | TNBC | Luminal | Selumetinib | MEK | MAPK | 0.4 | uM | 12269.155 | 1.1950 | 1.5010 | 0.7969 | |
| SUM185PE | TNBC | Luminal | Selumetinib | MEK | MAPK | 2 | uM | 12269.155 | 1.0646 | 1.1634 | 0.7969 | |
| SUM185PE | TNBC | Luminal | Selumetinib | MEK | MAPK | 10 | uM | 12269.155 | 1.1470 | 1.3755 | 0.7969 | |
| SUM185PE | TNBC | Luminal | Selumetinib | MEK | MAPK | 50 | uM | 12269.155 | 1.0160 | 1.0402 | 0.7969 | |
| SUM225CWN | HER2amp | Basal A | Selumetinib | MEK | MAPK | 0.000128 | uM | 12098.155 | 1.0586 | 1.1113 | 1.0503 | |
| SUM225CWN | HER2amp | Basal A | Selumetinib | MEK | MAPK | 0.00064 | uM | 12098.155 | 0.9879 | 0.9770 | 1.0503 | |
| SUM225CWN | HER2amp | Basal A | Selumetinib | MEK | MAPK | 0.0032 | uM | 12098.155 | 1.0620 | 1.1179 | 1.0503 | |
| SUM225CWN | HER2amp | Basal A | Selumetinib | MEK | MAPK | 0.016 | uM | 12098.155 | 0.9222 | 0.8516 | 1.0503 | |
| SUM225CWN | HER2amp | Basal A | Selumetinib | MEK | MAPK | 0.08 | uM | 12098.155 | 0.9217 | 0.8507 | 1.0503 | |
| SUM225CWN | HER2amp | Basal A | Selumetinib | MEK | MAPK | 0.4 | uM | 12098.155 | 0.9738 | 0.9501 | 1.0503 | |
| SUM225CWN | HER2amp | Basal A | Selumetinib | MEK | MAPK | 2 | uM | 12098.155 | 0.8794 | 0.7696 | 1.0503 |